Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Natalia Zeber-Lubecka, Maria Kulecka, Filip Ambrozkiewicz, Agnieszka Paziewska, Krzysztof Goryca, Jakub Karczmarski, Tymon Rubel, Wojciech Wojtowicz, Piotr Mlynarz, Lukasz Marczak, Roman Tomecki, Michal Mikula & Jerzy Ostrowski. (2016) Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes 7:5, pages 397-413.
Read now
Read now
Articles from other publishers (3)
V. N. Drozdov, K. I. Arefev, S. Yu. Serebrova, I. A. Komissarenko, E. V. Shikh & A. K. Starodubtsev. (2021) Role of antispasmodics in the treatment of irritable bowel syndrome. Meditsinskiy sovet = Medical Council:5, pages 155-164.
Crossref
Crossref
Brandon D. Kirby, Roy Al Ahmar, T. Ryan Withers, Meagan E. Valentine, Monica Valentovic, Timothy E. Long, James R. Gaskins & Hongwei D. Yu. (2019) Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice. Antimicrobial Agents and Chemotherapy 63:7.
Crossref
Crossref
Jan Juřica & Radek Kroupa. (2017) Pharmacotherapy of irritable bowel syndrome. Praktické lékárenství 13:2, pages 52-59.
Crossref
Crossref